Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Caroen

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Nucleocapsid as a next-generation COVID-19 vaccine candidateBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Nucleocapsid as a next-generation COVID-19 vaccine candidateBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 6